Bergmann Anthony 4

What Happened

• Anthony Bergmann, Chief Financial Officer of Capricor Therapeutics (CAPR), exercised options and immediately sold the resulting shares in two batches. On 2026-06-22 he exercised 500 shares at $3.18 (cost $1,590) and sold 500 shares at $30.00 for $15,000. On 2026-06-24 he exercised 400 shares at $3.18 (cost $1,272) and sold 400 shares at $30.00 for $12,000. Net proceeds from the sales totaled $27,000 while the exercise cost totaled $2,862. The filing also reports corresponding derivative exercise/conversion entries at $0.00 for the same share counts.

Key Details

• Transaction dates and prices:
  • 2026-06-22: exercised 500 shares @ $3.18; sold 500 shares @ $30.00
  • 2026-06-24: exercised 400 shares @ $3.18; sold 400 shares @ $30.00
• Total sold: 900 shares for $27,000; total exercised cost: $2,862.
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Footnotes:
  • F1: Sales were made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Bergmann in December 2025.
  • F2: The filing notes a vesting schedule (1/48th monthly beginning Feb 1, 2022) for the underlying awards.
• No indication in the provided excerpt that the filing was late.

Context

• This pattern—exercising options and selling the resulting shares on or about the same dates—is commonly a sell-to-cover or cashless exercise approach; here the sales occurred the same days as the exercises. The reported 10b5-1 plan means the sales were executed under a pre-established trading plan (routine trading), not an ad hoc sale. These entries are factual reporting of insider transactions and do not by themselves indicate the insider’s future view of the company.